The notices it replaced
Its page was not saved, so the notices it replaced are not known.
Who won it before
248 competing awards (new and renewals) from FY2014 to FY2025 under this notice and the notices it replaced: $213,177,248 in first-year total cost, median $774,443.
Most frequent study sections
- Special Emphasis Panel[ZRG1 ETTN-M (11)]21
- Special Emphasis Panel[ZRG1 SBIB-T (10)]17
- Special Emphasis Panel[ZRG1 CVRS-C (10)]14
- Special Emphasis Panel[ZRG1 IDM-X (10)]12
- Special Emphasis Panel[ZRG1 ETTN-C (10)]9
Most frequent institutions
- BIOSENSICS, LLC4
- FOX CHASE CHEMICAL DIVERSITY CENTER, INC3
- RADIKAL THERAPEUTICS, INC.3
- ADVANCED BRAIN MONITORING, INC.2
- ALDATU BIOSCIENCES, INC.2
| FY | Project | PIs | Institution | First-year cost | Study section |
|---|---|---|---|---|---|
| 2017 | A Novel Device for Optimal and Personalized Fluid Therapy in Septic Shock Patients1R44GM123799-01 | BURNETT, DANIEL ROGERSCONNOR, MICHAEL JOSEPHJUNCOS, LUIS A. | POTRERO MEDICAL, INC., CA | $1,685,221 | ZRG1 |
| 2017 | Eliminating Ventricular Tachycardia: First in Human Clinical Trial using the Durablate™ Catheter1R44HL132746-01A1 | CURLEY, MICHAEL G | THERMEDICAL, INC., MA | $1,673,144 | ZRG1 |
| 2017 | Ultrasound Enhanced Low Dose Drug Delivery: Quantifying Uptake, Retention and Biodistribution1R44HL139241-01 | KILROY, JOSEPH P. | SOUNDPIPE, LLC, VA | $1,588,126 | ZRG1 |
| 2017 | Advanced therapeutic for Parkinson's Disease1R44NS103695-01 | WERNER, MILTON H. | INHIBIKASE THERAPEUTICS, GA | $1,554,020 | ZRG1 |
| 2017 | Wearable Sensors for Quantitative Assessment of Motor Impairment in Huntington's Disease1R44NS103648-01 | GWIN, JOSEPH T | BIOSENSICS, LLC, MA | $1,314,945 | ZRG1 |
| 2017 | Discovering a Disease Modifying Therapeutic to Treat Huntington's Disease1R44AG059272-01A1 | SIPPOLA-THIELE, MARIA SIRPA | CHAPERONE THERAPEUTICS, INC., NC | $1,300,009 | ZRG1 |
| 2017 | A robust kit, standards, and software for identifying RNA binding protein targets1R44HG009875-01 | SHISHKIN, ALEXANDER A | ECLIPSE BIOINNOVATIONS INC, CA | $1,278,018 | ZRG1 |
| 2017 | Development of New Improved Perflutren Ultrasound Contrast Agent1R44HL137447-01A1 | PORTER, THOMAS RUNGER, WYATT DANIEL | MICROVASCULAR THERAPEUTICS, LLC, AZ | $1,229,385 | ZRG1 |
| 2017 | Validation of targets for therapeutic intervention in NASH1R44DK115301-01 | WAMHOFF, BRIAN ROBERT | HEMOSHEAR THERAPEUTICS, LLC, VA | $1,211,258 | ZRG1 |
| 2017 | AVGN7, a Novel Gene Therapeutic for Treating Cancer Cachexia1R44CA221539-01 | RODGERS, BUEL | AAVOGEN, INC., MD | $1,206,955 | ZRG1 |
| 2017 | IND-enabling development of a biomimetic peptide drug for macular edema1R44EY027632-01 | PANDEY, NIRANJAN B | ASCLEPIX THERAPEUTICS, INC., MD | $1,165,695 | ZRG1 |
| 2017 | BiVACOR Rotary Total Artificial Heart1R44HL137454-01A1 | TIMMS, DANIEL | BIVACOR, INC., TX | $1,158,587 | ZRG1 |
| 2017 | Standardization of a Fluidic In Vitro Exposure System for IVIVE Predictive Toxicity Data1R44GM123796-01 | MCCLELLAND, RANDALL EDWINMOSEDALE, MERRIE | SCIKON INNOVATION, INC., NC | $1,085,817 | ZRG1 |
| 2017 | An Oral Ultra Long-Acting Ivermectin for Malaria Elimination1R44TR001889-01A1 | BELLINGER, ANDREW MARTIN | LYNDRA THERAPEUTICS, INC., MA | $1,047,601 | ZRG1 |
| 2017 | Monitoring immune response to immunotherapies in cancer patients with VisAcT PET tracer1R44CA221624-01 | GOTH, SAMUEL RAYLEVI, JELENA | CELLSIGHT TECHNOLOGIES, INC., CA | $1,020,143 | ZRG1 |
| 2017 | A phase IIA trial for the safety and tolerability of CD24Fc in prophylaxis of graft vs host disease.1R44CA221513-01 | DEVENPORT, MARTINDEVINE, STEVEN M.REDDY, PAVAN | ONCOIMMUNE, INC., MD | $1,017,478 | ZRG1 |
| 2017 | Predicting DILI liability by transcription factor profiling1R44GM125469-01 | MAKAROV, SERGEI S | ATTAGENE, INC., NC | $1,016,149 | ZRG1 |
| 2017 | Combining faster detection with ID: a new paradigm for mycobacterial culture1R44AI128777-01 | RHODES, PAUL | SPECIFIC DIAGNOSTICS, INC., CA | $1,000,000 | ZRG1 |
| 2017 | Development of methionyl-tRNA synthetase inhibitors for Gram positive bacterial infections1R44AI134190-01 | LIPKA, ELKE | TSRL, INC., MI | $1,000,000 | ZRG1 |
| 2017 | A Phase 2 clinical trial of topical uracil for the prevention of capecitabine induced hand-foot syndrome1R44CA213519-01 | ISAACMAN, STEVENROWINKSY, ERIC K | NANOMETICS, LLC, CA | $999,914 | ZRG1 |
| 2017 | Development of Chemistry, Manufacturing, and Control Standards for PGC and PGC-dANP1R44HL134448-01A1 | CASTILLO, GERARDO M. | PHARMAIN CORPORATION, WA | $999,661 | ZRG1 |
| 2017 | Development of an H2O2-inactivated chikungunya virus vaccine1R44AI128990-01 | AMANNA, IAN JAMESSLIFKA, MARK K | NAJIT TECHNOLOGIES, INC., OR | $999,652 | ZRG1 |
| 2017 | Clinical Development of JS-K for the Treatment of Cancer1R44CA221570-01 | NOWOSLAWSKI, JOSEPH FELIX | JSK THERAPEUTICS, INC., UT | $999,183 | ZRG1 |
| 2017 | Development of GIFT4: a B cell focused immunotherapy for cancer1R44CA217365-01 | GUYRE, PAUL | CELDARA MEDICAL, LLC, NH | $999,088 | ZRG1 |
| 2017 | Immune Deficient Mosquitoes for Improved Malaria Sporozoite Vaccine Manufacture1R44AI131806-01A1 | BILLINGSLEY, PETER F. | SANARIA, INC., MD | $998,817 | ZRG1 |
| 2017 | Rapid Low Cost Phenotypic Antibiotic Susceptibility Testing.1R44AI131963-01 | RHODES, PAUL | SPECIFIC DIAGNOSTICS, INC., CA | $998,141 | ZRG1 |
| 2017 | PANDAA for rapid genotyping of HIV-1 infected patients failing protease inhibitor ART in resource-limited settings1R44AI128974-01 | MACLEOD, IAIN JAMES | ALDATU BIOSCIENCES, INC., MA | $998,024 | ZRG1 |
| 2017 | Advancing a novel potent Zika virus specific nucleoside analog to the clinic1R44AI129024-01A1 | KLUMPP, KLAUS | RIBOSCIENCE, LLC, CA | $993,605 | ZRG1 |
| 2017 | ZW800-1: The 1st Zwitterionic NIR Fluorophore for Cancer Imaging & Ureter Mapping1R44CA210820-01A1 | FRANGIONI, JOHN V | CURADEL, LLC, MA | $989,401 | ZRG1 |
| 2017 | Preclinical development of PPCM vaginal contraceptive to submit IND.1R44HD092206-01 | NORTH, BARBARA BESTOLDHAM, MICHAEL JWALLER, DONALD PWEITZEL, MARY B | YASO THERAPEUTICS INC, TX | $985,250 | ZRG1 |
| 2017 | Commercialization of low cost, disposable, point-of-care molecular diagnostic device for sexually transmitted infections1R44AI134565-01 | LONEY, GREGORY C | VISBY MEDICAL, INC., CA | $980,734 | ZRG1 |
| 2017 | Development of two simple and robust point-of-care assays for detection and therapy monitoring of hepatitis B in resource-limited settings1R44AI132034-01A1 | LEE, HELEN H | DIAGNOSTICS FOR THE REAL WORLD, LTD, CA | $968,003 | ZRG1 |
| 2017 | Monitoring and Stabilizing Behavioral Rhythms to Improve Mental Health1R44MH113520-01 | FRANK, ELLEN | HEALTH RHYTHMS, INC., NY | $964,251 | ZRG1 |
| 2017 | A robust platform for high-throughput single-cell genetic variation analysis1R44HG009465-01A1 | EASTBURN, DENNIS J | MISSION BIO, INC., CA | $951,385 | ZRG1 |
| 2017 | Novel MRI Contrast Agent for Detection of Beta Amyloid1R44AG051292-01A1 | WORKING, PETER | ALZECA BIOSCIENCES, INC., TX | $942,582 | ZRG1 |
| 2017 | A rapid, culture-free whole genome approach for characterizing complex metagenomics samples1R44GM123907-01 | PUTNAM, NICHOLAS HELMS | DOVETAIL GENOMICS, LLC, CA | $938,049 | ZRG1 |
| 2017 | Glycosaminoglycan-Interacting Small Molecule (GISMO) as Alzheimer's Therapeutics1R44AG056231-01A1 | GREGOR, PAUL | GISMO THERAPEUTICS, INC., NY | $933,415 | ZRG1 |
| 2017 | RetiVue DR, a point and shoot, non-mydriatic, widefield retinal camera for diabetic eye screening1R44EY028484-01 | LAI, MINGNETLAND, PETER AOSANAI, YOJI | RETIVUE, VA | $926,693 | ZRG1 |
| 2017 | A New Filter Paper Technology for Flavivirus Collection, Shipping, and Analysis1R44AI132032-01 | HOGAN, MICHAEL E.LANGENBACH, KURT JOHNNASARABADI, SHANAVAZ | GENTEGRA, LLC, CA | $909,182 | ZRG1 |
| 2017 | Tailored Drug Titration through Artificial Intelligence1R44HL132622-01A1 | VOSKERICIAN, GABRIELA | OPTIMA INTEGRATED HEALTH, INC., CA | $849,047 | ZRG1 |
| 2017 | A Single-Cell Device to Detect Pathogenic Cell Populations in Bone Marrow Disease1R44EB023777-01A1 | MCCONNELL, TIMOTHY SZHOU, JING | ISOPLEXIS, INC., DE | $845,621 | ZRG1 |
| 2017 | Long-acting ghrelin for the treatment of cancer cachexia1R44CA213844-01 | SOLIMAN, TARIK | EXTEND BIOSCIENCES, INC., MA | $832,924 | ZRG1 |
| 2017 | Magnetic Duodeno-Ileal Bypass for Metabolic Syndrome in Rhesus Monkeys1R44DK112453-01A1 | HARRISON, MICHAEL R | MAGNAMOSIS, INC., CA | $829,853 | ZRG1 |
| 2017 | Retinal tissue derived from human pluripotent stem cells for vision restoration1R44EY027654-01A1 | NASONKIN, IGOR O.PETERSEN-JONES, SIMONSEILER, MAGDALENE J | BIOTIME, INC., CA | $816,848 | ZRG1 |
| 2017 | Broadly neutralizing(BN) pan-IgE supersite vaccine for allergic asthma1R44AI126680-01A1 | CHEN, SWEY-SHEN | IGE THERAPEUTICS, INC., CA | $813,544 | ZRG1 |
| 2017 | Implementing an innovative suite of mobile applications for depression and anxiety.1R44MH114725-01 | NAIK, SMIT V | ADAPTIVE HEALTH, INC., IL | $810,676 | ZRG1 |
| 2017 | Monoclonal Sandwich ELISA for Serum Erythroferrone for Clinical Assessment of Ineffective Erythropoiesis1R44DK113841-01 | OSTLAND, VAUGHN E | INTRINSIC LIFESCIENCES, LLC, CA | $810,487 | ZRG1 |
| 2017 | Suction Device for Control and Accuracy of Transseptal Access1R44HL135937-01A1 | KASSAB, GHASSAN SMANSFIELD, GEORGE A | 3DT HOLDINGS, LLC, CA | $808,638 | ZRG1 |
| 2017 | Rapid detection of minimal residual disease in acute myeloid leukemia from peripheral blood1R44CA213595-01 | MULLER, ROLF | BIOFLUIDICA, INC, CA | $798,225 | ZRG1 |
| 2017 | Development of a nanoemulsion-adjuvanted prophylactic HSV-2 vaccine1R44AI126964-01A1 | FATTOM, ALI I. | BLUEWILLOW BIOLOGICS, INC., MI | $798,081 | ZRG1 |
| 2017 | Stream Dx: accurate and efficient, point-of-care uroflometry for improved diagnosis, monitoring, and post-treatment evaluation of LUTS1R44DK113878-01 | HOTALING, JAMESMCCLELLAN, SCOTT BRADFORD | STREAM DX, INC., UT | $798,054 | ZRG1 |
| 2017 | Optimization and Pre-Clinical Studies of a Protein Therapeutic for Recruiting Brown Adipocytes1R44DK113877-01A1 | BOSS, OLIVIER | ENERGESIS PHARMACEUTICALS, INC., MA | $793,958 | ZRG1 |
| 2017 | Development of Novel Targeted Chemotherapeutics for the Treatment ofMalignant Pleural Mesothelioma1R44CA221543-01 | SORGI, FRANK L | FLAG THERAPEUTICS, INC., NC | $787,067 | ZRG1 |
| 2017 | RehabTouch: A mixed-reality gym for rehabilitating the hands, arms, trunk, and legs after stroke1R44AG059256-01A1 | ROWE, JUSTIN | FLINT REHABILITATION DEVICES, CA | $775,488 | ZRG1 |
| 2017 | Development of the PTP1B inhibitor MSI-1436 for therapeutic stimulation of heart regeneration following acute myocardial infarction1R44HL139161-01 | YIN, VIRAVUTH P | REVIDIA THERAPEUTICS, INC, ME | $769,681 | ZRG1 |
| 2017 | Rapid, Near Patient Nucleic Acid Testing for Congenital Cytomegalovirus (CMV) Infection1R44DC016576-01 | NORTON, SCOTT MICHAEL | BAEBIES, INC., NC | $763,182 | ZRG1 |
| 2017 | Personalized precision dosing of biologic therapies in oncology1R44CA217336-01A1 | MESSMER, BRADLEY T | ABREOS BIOSCIENCES, INC., CA | $759,813 | ZRG1 |
| 2017 | Individualized Signal Processing Strategy :Phase II1R44DC016249-01 | KRAUSE, LEE STANLEY | SECURBORATION, INC., FL | $758,924 | ZRG1 |
| 2017 | Mouthpiece for mTBI Detection during Adolescent Contact and Collision Sports1R44HD090763-01A1 | HEDIN, DANIEL S | ADVANCED MEDICAL ELECTRONICS CORPORATION, MN | $756,497 | ZRG1 |
| 2017 | Pre-clinical Commercialization of a Synthetically Designed, Live-attenuated RSV Vaccine1R44AI131756-01 | MUELLER, STEFFEN | CODAGENIX, INC., NY | $755,377 | ZRG1 |
| 2017 | Exploratory Clinical Study to Evaluate the Potential Bioactivity of CLBS14 in Patients with Coronary Microvascular Dysfunction1R44HL135889-01 | LOSORDO, DOUGLAS W | LISATA THERAPEUTICS INC, NJ | $753,565 | ZRG1 |
| 2017 | Developing a novel antifungal targeting Gwt1 for the treatment of invasive aspergillosis and rare mold infections1R44AI131864-01A1 | SHAW, KAREN JOYSTEINBACH, WILLIAM J | AMPLYX PHARMACEUTICALS, INC., CA | $750,293 | ZRG1 |
| 2017 | Phase 3 Study of SGX301 and Fluorescent Light for Cutaneous T Cell Lymphoma1R44CA210848-01A1 | STRAUBE, RICHARD CONRAD | SOLIGENIX, INC., NJ | $750,000 | ZRG1 |
| 2017 | Clinical resting state fMRI software for surgical planning1R44GM125438-01 | OLSEN, TIMOTHY | RADIOLOGICS, INC., MO | $749,900 | ZRG1 |
| 2017 | Regulatory Validation of Standardized Clinical Laboratory Immunohistochemistry Controls1R44CA213476-01 | BOGEN, STEVEN A | BOSTON CELL STANDARDS INC, MA | $749,890 | ZRG1 |
| 2017 | Complete genome de novo assembly software for the emerging long read sequencing era1R44GM122120-01 | DURFEE, TIMOTHY J | DNASTAR, INC., WI | $749,795 | ZRG1 |
| 2017 | Bifunctional K-ATP channel opener and redox catalyst for treatment of hemorrhagic shock1R44GM122095-01 | SOUTHAN, GARRY JOHN | RADIKAL THERAPEUTICS, INC., MA | $749,330 | ZRG1 |
| 2017 | PET Imaging Agents for the in vivo Detection of TDP-431R44AG059278-01 | REITZ, ALLEN BERNARD | FOX CHASE CHEMICAL DIVERSITY CENTER, INC, PA | $745,412 | ZRG1 |
| 2017 | HLS-Highly-Sensitive, One-minute, Portable Diagnostic for Malaria Elimination1R44AI131810-01 | GALEN, PETER | HEMEX HEALTH, INC., OR | $740,558 | ZRG1 |
| 2017 | Development of a TRPA1 Antagonist Opioid-Sparing Analgesic for Chronic Pain1R44DA044900-01 | HERZ, JEFF MARK | ALGOMEDIX, INC., WA | $734,315 | ZRG1 |
| 2017 | ExoSOUND: An Acoustofluidic Device for Exosome Isolation1R44GM125439-01 | WANG, LIN | ASCENT BIO-NANO TECHNOLOGIES, INC., NC | $730,899 | ZRG1 |
| 2017 | A Hand-Held Robot to Cure BPH1R44EB024423-01A1 | HENDRICK, RICHARD JOSEPH | VIRTUOSO SURGICAL, INC., TN | $726,587 | ZRG1 |
| 2017 | Improved Electrode Material for High-Density Closed-Loop DBS.1R44NS103714-01 | PETROSSIANS, ARTIN | PLATINUM GROUP COATINGS, LLC, CA | $725,814 | ZRG1 |
| 2017 | Exosomal Drug Delivery1R44CA221487-01 | GUPTA, RAMESH CSPENCER, WENDY A | 3P BIOTECHNOLOGIES, INC., KY | $719,680 | ZRG1 |
| 2017 | Low-Cost Instrument-free Point-of-Care Diagnostic for Neisseria gonorrhoeae1R44AI129031-01 | DEAN, DEBORAH ANNEMITRA, DEBKISHORE | LUCIRA HEALTH, INC, CA | $716,689 | ZRG1 |
| 2017 | Evaluation of a Robotic Assisted Surgical System for Hearing Loss1R44DC016246-01 | HENSLEE, ALLAN | IOTAMOTION, INC., MN | $709,641 | ZRG1 |
| 2017 | Tools for Accelerating R&D for Historically Understudied Protein Kinases1R44TR001916-01 | ZUTSHI, REENA | LUCEOME BIOTECHNOLOGIES, LLC, AZ | $708,631 | ZRG1 |
| 2017 | Rapid saliva test for diagnostics of Neuro-Cognitive Disorder due to Traumatic Brain Injury (NCDT)1R44HD090817-01A1 | GRIFFIN, TIMOTHY J.PEACOCK, WILLIAM FRANKLINPUCCIO, AVA M.SOUTHERN, SARKA OLIVERA | GAIA MEDICAL INSTITUTE, INC., CA | $708,335 | ZRG1 |
| 2017 | Handheld ultrasound system for real-time thoracic epidural analgesia guidance1R44GM123791-01 | MAULDIN, FRANK WILLIAM | RIVANNA MEDICAL, INC., VA | $704,777 | ZRG1 |
| 2017 | Cartilage Regeneration with Tunable Inflammation Resistance1R44AG059310-01 | ESTES, BRADLEY T | CYTEX THERAPEUTICS INC., NC | $704,742 | ZRG1 |
| 2017 | Membrane-based vaccine with checkpoint blockade for triple negative breast cancer1R44CA221559-01 | KANNAN, KAMAL V.PACK, CHRISTOPHER D | METACLIPSE THERAPEUTICS CORPORATION, GA | $700,539 | ZRG1 |
| 2017 | Non-obtrusive tissue manipulation device for treatment of carpal tunnel syndrome1R44EB024713-01 | SON, JAE S. | PRESSURE PROFILE SYSTEMS, INC., CA | $683,645 | ZRG1 |
| 2017 | Development of Novel Adenosine Polymers for Coating Medical Devices1R44HL136233-01A1 | FORMAN, MERVYN B. | ADENOPAINT, LLC, GA | $683,627 | ZRG1 |
| 2017 | Development of Oral Small Molecule PCSK9 Antagonist1R44HL137449-01 | ELSHOURBAGY, NABIL AMOUSA, SHAKER A | SHIFA BIOMEDICAL CORPORATION, PA | $682,343 | ZRG1 |
| 2017 | Development of a Miniature Mass Spectromtry System for Point-of-Care Applications1R44GM119584-01 | OUYANG, ZHENG | PURSPEC TECHNOLOGIES, INC., IN | $672,527 | ZRG1 |
| 2017 | Orally-Bioavailable Peroxynitrite Decomposition Catalyst Targeting Post-Surgical Pain1R44DA044893-01 | DAX, SCOTT L | CERSCI THERAPEUTICS, INC., TX | $658,085 | ZRG1 |
| 2017 | A Novel Topical HSP90 Inhibitor (CTXT-102) in the Treatment of Mild to Moderate Plaque Psoriasis1R44AR071174-01A1 | GREK, CHRISTINA | REGRANION, LLC, SC | $654,034 | ZRG1 |
| 2017 | Independent Exoskeleton-Use through Robust Stand-to-Sit Safety1R44AG057267-01 | BECKER, ADAM | INNOVATIVE DESIGN LABS, INC., MN | $653,843 | ZRG1 |
| 2017 | Spring System for Permanent Relief of Urinary Obstruction related to Benign Prostatic Hyperplasia1R44DK112587-01A1 | DAMIANO, NICHOLAS | ZENFLOW, INC., CA | $636,601 | ZRG1 |
| 2017 | Reversing Isoniazid Resistance By Isotopic Substitution1R44AI129005-01A1 | TIMMINS, GRAHAM S | SPINCEUTICA, INC., NM | $586,360 | ZRG1 |
| 2017 | A Novel Device for Ultra-Rapid Non-Pharmacologic Ocular Anesthesia1R44EY028495-01 | CHALBERG, THOMAS W | IRENIX MEDICAL, INC., CA | $581,104 | ZRG1 |
| 2017 | A Novel Gyrase Inhibitor for the Treatment of Drug-susceptible and Multidrug-resistant Mycobacterium tuberculosis Infections1R44AI131749-01 | PUCCI, MICHAEL J | SPERO THERAPEUTICS, INC., MA | $564,718 | ZRG1 |
| 2017 | Characterizing Alzheimer's Disease with INSPECDS: Integrated Neurocognitive and Sleep-Behavior Profiler for the Endophenotypic Classification of Dementia Subtypes1R44AG054256-01A1 | BERKA, CHRIS | ADVANCED BRAIN MONITORING, INC., CA | $538,507 | ZRG1 |
| 2017 | Automated Objective Audiometry using Long Latency Steady State Responses1R44DC015920-01A1 | DELGADO, RAFAEL E | INTELLIGENT HEARING SYSTEMS, FL | $508,257 | ZRG1 |
| 2017 | Treatment of type 1 diabetes with human embryonic stem cell derived pancreatic beta-like cells1R44DK115257-01 | D'AMOUR, KEVIN | VIACYTE, INC., CA | $500,370 | ZRG1 |
| 2017 | Preclinical Validation of Novel High Affinity D2 Receptor Agonists for PET Neuroimaging1R44OD024615-01 | NEUMEYER, JOHN L | NATURAL PHARMACIA INTERNATIONAL, INC., MA | $499,999 | ZRG1 |
| 2017 | Liquid CO2 Flash Chromatography System1R44GM122107-01A1 | SCHLAKE, ROLF | APPLIED SEPARATIONS, INC., PA | $492,238 | ZRG1 |
| 2017 | Development of NSI-189, a novel neurogenic molecule, to prevent and treat diabetic neuropathy1R44NS103703-01 | JOHE, KARL K | NEURALSTEM, INC., MD | $491,049 | ZRG1 |
| 2017 | Enrichment-free Salmonella detection for food safety1R44AI134498-01 | KOERIS, MICHAEL SANDOR | SAMPLE6 TECHNOLOGIES, INC., MA | $489,513 | ZRG1 |
| 2017 | In vitro and in vivo efficacy of liposomal ciprofloxacin formulations against Mycobacterium avium and Mycobacterium abscessus1R44AI134572-01 | BERMUDEZ, LUIZ EDUARDOBLANCHARD, JAMES D | ARADIGM CORPORATION, CA | $486,599 | ZRG1 |
| 2017 | Self-Digitization Microfluidic Platform for Digital PCR1R44GM123797-01 | KREUTZ, JASON EUGENE | LAMPROGEN, INC., WA | $469,045 | ZRG1 |
| 2017 | New Treatment of the Brain in Niemann Pick C1R44NS098877-01A1 | PARDRIDGE, WILLIAM M | LIPOGENE COMPANY, INC., CA | $460,967 | ZRG1 |
| 2017 | Web Software to develop an RDoC-Compatible Adaptive Diagnostic Nosology, the SID-51R44MH108177-01A1 | BRODEY, BENJAMIN B | TELESAGE, INC., NC | $433,630 | ZRG1 |
| 2017 | An integrated transcriptomic and proteomic approach to antibody sequencing and repertoire characterization1R44GM122102-01 | CASTELLANA, NATALIE | DIGITAL PROTEOMICS LLC, CA | $388,404 | ZRG1 |
| 2017 | Portable Hearing Laboratory1R44DC016247-01A1 | PAVLOVIC, CASLAV VOJISLAV | BATANDCAT, INC., CA | $374,226 | ZRG1 |
| 2016 | BPN14770 Safety and Cognitive Effect in Young and Elderly Subjects1R44AG054243-01 | GURNEY, MARK E | TETRA DISCOVERY PARTNERS, INC., MI | $2,055,899 | ZRG1 |
| 2016 | Development of a novel drug treatment for decompensated heart failure.1R44HL131086-01A1 | MAHAN, LAWRENCE | MADELEINE PHARMACEUTICALS, INC., WI | $1,996,767 | ZRG1 |
| 2016 | Mobility Life: Monitoring Mobility in Daily Lives of People with Neurological Disease1R44AG055388-01 | EL-GOHARY, MAHMOUDHORAK, FAY BAHLING | APDM, INC., OR | $1,805,525 | ZRG1 |
| 2016 | A new reference panel to boost African American genotype imputation1R44HG009460-01 | AUTON, ADAM | 23ANDME, INC., CA | $1,758,557 | ZRG1 |
| 2016 | Improved Dosing and Refinement of a Cardiac Targeted Gene Therapy in a Swine Infarct Model1R44HL129782-01A1 | TEICHMAN, SAM | BEAT BIOTHERAPEUTICS CORPORATION, WA | $1,545,537 | ZRG1 |
| 2016 | Cyanalyzer A Medical Laboratory Device for the Rapid Diagnosis of Cyanide Exposure1R44NS097066-01A1 | HOBSON, STEPHEN TERRENCE | SEACOAST SCIENCE, INC., CA | $1,343,682 | ZRG1 |
| 2016 | Validation of a non-invasive technology to measure bilirubin in newborns1R44HD090778-01 | CLARKE, MICHAEL STEPHEN | BILICAM, LLC, WA | $1,297,065 | ZRG1 |
| 2016 | Highly Accelerated Simultaneous Multi-Slice Phase Contrast MRI1R44MH112210-01A1 | FEINBERG, DAVID ALAN | ADVANCED MRI TECHNOLOGY, LLC, CA | $1,287,772 | ZRG1 |
| 2016 | sHLA Protein Chip for Anti-HLA Antibody Screening and Monitoring1R44AI122642-01 | HOGAN, MICHAEL E. | GENOMICS USA, INC., TX | $1,281,226 | ZRG1 |
| 2016 | Therapeutic antibody for RSV1R44AI122360-01 | KAUVAR, LAWRENCE MICHAEL | TRELLIS BIOSCIENCE, INC., CA | $1,268,751 | ZRG1 |
| 2016 | A Novel Pharmacological Treatment for Neuropathic Pain1R44NS100173-01 | MOSKAL, JOSEPH | APTINYX, INC., IL | $1,249,376 | ZRG1 |
| 2016 | Advanced Human on a Chip Systems for Drug Discovery1R44TR001326-01A1 | HICKMAN, JAMES JSHULER, MICHAEL L | HESPEROS, LLC, FL | $1,241,321 | ZRG1 |
| 2016 | Real-time histopathology for intra-operative tumor margin delineation1R44CA206664-01 | FREUDIGER, CHRISTIANORRINGER, DANIEL | INVENIO IMAGING INC., CA | $1,218,888 | ZRG1 |
| 2016 | Bactericidal antibiotic for Vancomycin Resistant Enterococci1R44AI122426-01A1 | LAFLEUR, MICHAEL | ARIETIS, MA | $1,218,307 | ZRG1 |
| 2016 | Development of novel inhibitors of C1q for the treatment of Neurodegenerative diseases1R44AG054404-01 | SANKARANARAYANAN, SETHUYEDNOCK, TED | ANNEXON, INC., CA | $1,213,915 | ZRG1 |
| 2016 | Advancement to Clinical Candidate of Novel, Potent and Selective Chikungunya virus inhibitor series1R44AI122421-01 | PEVEAR, DANIEL C | VENATORX PHARMACEUTICALS, INC., PA | $1,139,136 | ZRG1 |
| 2016 | Development of an LXR agonist as first in class therapy for treatment of metastatic melanoma1R44CA206677-01A1 | KURTH, ISABEL | RGENIX, INC., NY | $1,117,983 | ZRG1 |
| 2016 | An Active Hemostatic Clamping Device for Bloodless Surgery and Trauma1R44GM114934-01A1 | MITCHELL, STUART B | NOVUSON SURGICAL, INC., WA | $1,076,073 | ZRG1 |
| 2016 | Portable iridium-electrode inhaled Nitric Oxide generator for treatment of lung diseases1R44TR001704-01 | SILKOFF, PHILIP E | THIRD POLE, INC., MA | $1,073,276 | ZRG1 |
| 2016 | Validation of a rapid point-of-care breath test for breast cancer1R44CA203019-01A1 | PHILLIPS, MICHAEL | MENSSANA RESEARCH, INC., NJ | $1,071,867 | ZRG1 |
| 2016 | Development of Intrasaccular Flow Disrupters for Small and Ruptured Aneurysms1R44NS097038-01 | KALLMES, DAVID FPATTERSON, WILLIAM ROBERT | SEQUENT MEDICAL, INC., CA | $1,051,119 | ZRG1 |
| 2016 | A prospective, multi-center pivotal study of the LUM Imaging System for real-time, in vivo margin assessment in breast conserving surgery1R44CA211013-01 | LEE, W. DAVID | LUMICELL, INC., MA | $1,033,123 | ZRG1 |
| 2016 | Colon cancer risk-stratification via optical analysis of rectal ultrastructure1R44CA199667-01A1 | NGUYEN, THE-QUYENWALI, RAMESH K | AMERICAN BIOOPTICS, LLC, IL | $1,030,462 | ZRG1 |
| 2016 | A NOVEL NEUROPROTECTIVE THERAPY FOR ALZHEIMER’S DISEASE1R44AG053084-01 | ABRAHAM, CARMELAABRAHAM, MENACHEMWINDISCH, MANFRED | KLOGENE THERAPEUTICS, INC., MA | $1,022,134 | ZRG1 |
| 2016 | Technology to Select Candidates for Prophylactic Treatments to Prevent Sporadic Breast Cancers1R44CA206774-01A1 | POOLA, INDIRA NONE | SILBIOTECH, INC., MD | $1,009,044 | ZRG1 |
| 2016 | DEVELOPMENT OF TOPICAL ANTIVIRAL AGENTS FOR TREATING MOLLUSCUM CONTAGIOSUM1R44AI125005-01 | SCOTT, RICHARD W | FOX CHASE CHEMICAL DIVERSITY CENTER, INC, PA | $1,002,030 | ZRG1 |
| 2016 | A glycolipid adjuvant to promote dose sparing, accelerate immunization schedules and extend durability of high-level protection with a live attenuated sporozoite malaria vaccine1R44AI125009-01 | HOFFMAN, STEPHEN LEV | SANARIA, INC., MD | $1,000,000 | ZRG1 |
| 2016 | A Phase I Dose-escalation Study of Intraperitoneal CYN101 as Consolidation Immunotherapy in Women with Residual or Recurrent Ovarian Cancer Status after Chemotherapy1R44CA206606-01 | MERUELO, DANIELWINRAM, SCOTT BUDD | CYNVEC, LLC, NY | $995,814 | ZRG1 |
| 2016 | An Integrated Device for Rapid Bacteremia Diagnosis from Whole Blood1R44AI124726-01 | SINGER, ALON | HELIXBIND, INC., MA | $985,030 | ZRG1 |
| 2016 | HBI-002 to Treat Delayed Graft Function in Kidney Transplant1R44DK111260-01 | GOMPERTS, EDWARDOTTERBEIN, LEO E | HILLHURST BIOPHARMACEUTICALS, INC., CA | $862,618 | ZRG1 |
| 2016 | Novel peptide-coated suture for cleft lip and palate repair1R44DE026080-01 | SOO, CHIAZHENG, ZHONG | SCARLESS LABORATORIES, INC., CA | $860,274 | ZRG1 |
| 2016 | CTL for supertype natural IgE cytotoxic peptide (nECP) to guard against allergic asthma1R44AI122358-01 | CHEN, SWEY-SHEN | IGE THERAPEUTICS, INC., CA | $853,476 | ZRG1 |
| 2016 | Development of protein therapeutic for acute kidney injury1R44DK112403-01 | TAN, TAO | TRIM-EDICINE, INC., OH | $833,693 | ZRG1 |
| 2016 | Innovative Image-Guided Device for Beating Heart Mitral Valve Repair1R44HL131101-01 | WILSON, PETER MCKEAGE | HARPOON MEDICAL, INC., MD | $830,130 | ZRG1 |
| 2016 | Magnetic Mini Mover Device for the Treatment of Pectus Excavatum1R44HL134520-01 | HARRISON, MICHAEL R | MAGNETS-IN-ME, LLC, CA | $825,332 | ZRG1 |
| 2016 | Establishing In Vivo Proof of Concept of Brown Adipogenesis Using Approved Drugs1R44DK109860-01 | BOSS, OLIVIER | ENERGESIS PHARMACEUTICALS, INC., MA | $812,187 | ZRG1 |
| 2016 | WayToServe Español: A Culturally-Appropriate Online Responsible Beverage Service Training for Spanish-Speaking Servers1R44MD010405-01A1 | WOODALL, W GILL | KLEIN BUENDEL, INC., CO | $798,184 | ZRG1 |
| 2016 | Wearable Patch Reader for Peripheral Artery Disease1R44HL134532-01 | WISNIEWSKI, NATALIE ANN | PROFUSA, INC., CA | $787,161 | ZRG1 |
| 2016 | High-Resolution Magnetoencephalography using Atomic Magnetrodes1R44MH110288-01 | ALEM, ORANG | QUSPIN, CO | $772,932 | ZRG1 |
| 2016 | Buccal Nanocytological Risk Stratification to Personalize Lung Cancer Screening1R44CA206844-01A1 | SUBRAMANIAN, HARIHARAN | NANOCYTOMICS, LLC, IL | $769,969 | ZRG1 |
| 2016 | Development of novel isoflavone drugs as broad spectrum antivirals1R44AI115824-01A1 | BEDARD, KRISTIN MGALE, MICHAEL | KINETA, INC., WA | $757,817 | ZRG1 |
| 2016 | Production of therapeutic human polyclonal antibodies against influenza viruses1R44AI117976-01A1 | HUBER, VICTOR CHESTERJIAO, JINAN | SAB BIOTHERAPEUTICS, INC., SD | $756,080 | ZRG1 |
| 2016 | Iridium-electrode inhaled Nitric Oxide generator for treatment of hypoxic respiratory failure in neonates1R44HL134429-01 | SILKOFF, PHILIP E | THIRD POLE, INC., MA | $754,483 | ZRG1 |
| 2016 | Improving vaccine development through high-throughput immunogenicity screening.1R44AI127039-01 | BROOKS, BENJAMIN DELBERTCOHEN, GARY HEISENBERG, ROSELYN JMYSZKA, DAVID G. | CARTERRA, INC., UT | $751,913 | ZRG1 |
| 2016 | Recombinant Hyperimmune Gammaglobulin for Primary Immunodeficiency1R44AI124901-01 | JOHNSON, DAVID SCOTT | GIGAGEN, INC., CA | $750,198 | ZRG1 |
| 2016 | Fracture Risk Assessment Software for Skeletal Metastasis1R44AR069421-01 | GWIN, JOSEPH T | BIOSENSICS, LLC, MA | $750,000 | ZRG1 |
| 2016 | A pro-resolution lipid mediator for treatment of rheumatoid arthritis1R44AR070686-01 | JAGTAP, PRAKASH G | RADIKAL THERAPEUTICS, INC., MA | $750,000 | ZRG1 |
| 2016 | Tau Oligomer Platform Validation Using Lead Series Candidate in htau Mice1R44AG053150-01 | MOE, JAMES G. | OLIGOMERIX, INC, NY | $749,795 | ZRG1 |
| 2016 | Development and testing of MRI-mediated radiofrequency ablation system and probes1R44CA203276-01A1 | ACKERMAN, JEROME LNEVO, EREZ | ROBIN MEDICAL, INC., MD | $749,066 | ZRG1 |
| 2016 | Development of a non-addictive analgesic targeting opioid receptor heteromers.1R44DA041912-01 | YEKKIRALA, AJAY S | BLUE THERAPEUTICS, INC., MA | $746,689 | ZRG1 |
| 2016 | Exploratory Chemistry on a new antibiotic1R44AI122425-01A1 | HUGHES, DALLAS | NOVOBIOTIC PHARMACEUTICALS, LLC, MA | $746,210 | ZRG1 |
| 2016 | Prevention of Syncope with GSN Stimulation1R44HL132656-01A1 | LEVIN, HOWARD | CORIDEA, LLC, NY | $740,435 | ZRG1 |
| 2016 | Development of a novel quadrivalent seasonal influenza vaccine using E.coli production technology1R44AI125168-01A1 | LI, SHENGQIANG | SCIOGEN, LLC, CA | $737,500 | ZRG1 |
| 2016 | Assessment of Bioreactor-Derived Human Platelet Quality, Storage Profile, Safety, and Function1R44HL131050-01 | KARLSSON, SVEN M | STELLULAR BIO, INC., MA | $729,375 | ZRG1 |
| 2016 | Developing a Novel, Fungicidal Therapeutic to Treat Coccidioidomycosis1R44AI125017-01 | SHAW, KAREN JOY | AMPLYX PHARMACEUTICALS, INC., CA | $728,595 | ZRG1 |
| 2016 | Innovating Tablet-Based Cognitive Assessment for CNS Disorders of Aging1R44AG053121-01 | KEEFE, RICHARD S | VERASCI, LLC, NC | $711,254 | ZRG1 |
| 2016 | Integrated Neurocognitive and Sleep-Behavior Profiler for the Endophenotypic Classification of Dementia Subtypes (INSPECDS)1R44AG050326-01A1 | BERKA, CHRIS | ADVANCED BRAIN MONITORING, INC., CA | $710,663 | ZRG1 |
| 2016 | Allosteric MIF Inhibitors for Rheumatoid Arthritis Therapy1R44AR067569-01A1 | ANTHONY, KAREN G.CIRILLO, PIER FRANCESCO | L2 DIAGNOSTICS, LLC, CT | $694,516 | ZRG1 |
| 2016 | Internally Calibrated Chromatin Immunoprecipitation Using Barcoded Nucleosomes1R44HG008907-01 | SUN, ZU-WEN | EPICYPHER, INC., NC | $676,616 | ZRG1 |
| 2016 | 2-Hydroxybenzylamine for the prevention of Alzheimer's disease: Initial evaluation in humans1R44AG055184-01 | RATHMACHER, JOHN A | METABOLIC TECHNOLOGIES, INC., IA | $672,479 | ZRG1 |
| 2016 | An interactive, wearable device for measuring and motivating hand use after stroke1R44HD086953-01 | FRIEDMAN, NIZAN | FLINT REHABILITATION DEVICES, CA | $658,518 | MRS |
| 2016 | An HIV Viral Load Assay for the Point-Of-Care1R44AI124964-01A1 | FERNANDEZ-SUAREZ, MARTAOYUGI, JULIUS OTIENO | DAKTARI DIAGNOSTICS, INC., MA | $649,571 | ZRG1 |
| 2016 | Novel Androgen Receptor Degraders to Treat Castration-Resistant Prostate Cancer1R44CA203199-01 | TAYLOR, IAN | ARVINAS, INC., CT | $648,400 | ZRG1 |
| 2016 | I Live Inspired: Individually Tailored and Integrated Social Support Network for Tobacco Cessation1R44DA041904-01 | DEUTSCH, CHRISTOPHER | LIVE INSPIRED, LLC, DC | $642,136 | ZRG1 |
| 2016 | A Quantitative Epigenetic Test for Guiding Smoking Cessation Therapy1R44CA213507-01 | PHILIBERT, ROBERT A | BD HOLDING, INC., IA | $642,097 | ZRG1 |
| 2016 | Large animal study on deeply porous transcutaneous pylon for direct skeletal attachment1R44HD090768-01 | PITKIN, MARK | POLY-ORTH INTERNATIONAL, MA | $621,050 | ZRG1 |
| 2016 | Predictive tool to prevent overdose in patients treated with prescription opioids1R44DA042655-01 | SASINOWSKI, MACIEK | VENEBIO GROUP, LLC, VA | $607,585 | ZRG1 |
| 2016 | Development of a Telehealth Platform for Treatment with the SpeechVive Device1R44DC014867-01A1 | HUBER, JESSICA ELAMBERT, ASHLEIGH | SPEECHVIVE, INC., IN | $597,381 | ZRG1 |
| 2016 | Sustained release gel enabling one-stage treatment of prosthetic joint infection1R44AR070685-01 | OVERSTREET, DEREK JAMESVERNON, BRENT L | SONORAN BIOSCIENCES, INC., AZ | $564,985 | ZRG1 |
| 2016 | New Test System for Blood Lead Levels in Children1R44HD087097-01 | BONAVENTURA, CELIA JHENKENS, ROBERT W | ALDERON BIOSCIENCES, INC., NC | $554,446 | ZRG1 |
| 2016 | Platform for practical delivery of oral autoantigens as co-therapies for neurological disease1R44NS098830-01 | PILLER, KENNETH J | SOYMEDS, INC., NC | $548,420 | ZRG1 |
| 2016 | SMALL MOLECULE THERAPY FOR ALZHEIMER'S DISEASE1R44AG050336-01 | SUNDARAM, PAZHANI | RECOMBINANT TECHNOLOGIES, LLC, CT | $519,209 | ZRG1 |
| 2016 | LASER TISSUE WELDING: BREACHING BARRIERS IN THE SURGICAL MANAGEMENT OF THE PANCREAS1R44CA203052-01 | BARAKAT, OMARWADIA, YASMIN | LASER TISSUE WELDING, INC., TX | $500,000 | ZRG1 |
| 2016 | Brain DNA Therapeutics with Trojan Horse Liposomes1R44NS097040-01A1 | PARDRIDGE, WILLIAM M | LIPOGENE COMPANY, INC., CA | $499,613 | ZRG1 |
| 2016 | Development of Rodent Self-Administration Vapor Inhalation Chambers for THC1R44DA041967-01 | COLE, MAURY D. | LA JOLLA ALCOHOL RESEARCH, INC., CA | $499,190 | ZRG1 |
| 2016 | Superficially Porous Silica Based Chiral Stationary Phases for High Efficiency and High Speed Pharmaceutical Analysis and Purification1R44GM117783-01 | LEE, JAUH TZUOH | AZYP, LLC, TX | $486,100 | ZRG1 |
| 2016 | A Quantitative Systems Pharmacology Software Platform for Biologics: reduce costs and accelerate development of innovative biotherapeutics1R44GM116214-01A1 | APGAR, JOSHUA | APPLIED BIOMATH, LLC, MA | $469,938 | ZRG1 |
| 2016 | A high volume parallel acoustic flow cytometer for the detection of rare cells or particles in a large sample volume with a low background concentration (i.e. very dilute samples).1R44GM117649-01 | GRAVES, STEVEN W | ETA DIAGNOSTICS, INC., NM | $468,750 | ZRG1 |
| 2016 | Hemodynamic Noninvasive Skin Cancer Diagnostics1R44CA203038-01A1 | CHACHISVILIS, MIRIANAS | VERISKIN, INC., CA | $455,835 | ZRG1 |
| 2016 | Mutant transgenic plant cells as a novel source of drugs1R44AA025804-01 | LITTLETON, JOHN M. | NAPROGENIX, INC, KY | $455,773 | ZRG1 |
| 2015 | Overcoming the last barrier to commercialization of virus-specific T cell therapy1R44AI118693-01A1 | WILSON, JOHN | WILSON WOLF MANUFACTURING CORPORATION, MN | $1,599,561 | ZRG1 |
| 2015 | A kit for massively parallel single cell gene expression analysis1R44HG008323-01 | FAN, CHRISTINA | CELLULAR RESEARCH, INC., CA | $1,512,400 | ZRG1 |
| 2015 | Treatment of congenital heart disease associated pulmonary hypertension1R44HD082865-01 | SALZMAN, ANDREW LURIE | RADIKAL THERAPEUTICS, INC., MA | $1,500,000 | ZRG1 |
| 2015 | CATHEPSIN L INHIBITORS AS PAN-CORONAVIRUS THERAPEUTICS1R44AI118063-01 | GREENBAUM, DORON | PHELIX THERAPEUTICS, LLC, PA | $1,475,511 | ZRG1 |
| 2015 | A new class of non-opioid analgesics for use in chronic pain management1R44DA038968-01A1 | BUNKER, KEVIN D | KALYRA PHARMACEUTICALS, INC., CA | $1,242,938 | ZRG1 |
| 2015 | Anticoagulum Cardiac RF Ablation Catheter (Direct Phase II)1R44HL127758-01 | SIGG, DANIEL | FOCUSSTART, LLC, MN | $1,220,224 | ZRG1 |
| 2015 | Cross-Protective Multivalent Vaccine for Tick-Borne Flaviviruses1R44AI118017-01 | CLEMENTS, DAVID E | HAWAII BIOTECH, INC., HI | $1,156,549 | ZRG1 |
| 2015 | Optimization and Validation of an Indicator Cell Assay for Blood-Based Diagnosis of Alzheimers Disease1R44AG051282-01 | SMITH, JENNIFER JOY | PRECYTE, INC., MD | $1,151,844 | ZRG1 |
| 2015 | First-in-Class Macrocyclic Peptide Therapeutic For Rheumatoid Arthritis1R44AR068833-01 | TRAN, DAT QUANG | ORYN THERAPEUTICS, LLC, CA | $1,142,534 | ZRG1 |
| 2015 | Clinical Evaluation of T3D-959 as a Potential Disease Remedial Therapeutic for the Treatment of Alzheimer's Disease1R44AG049510-01 | DE LA MONTE, SUZANNE M.DIDSBURY, JOHN | T3D THERAPEUTICS, INC., NC | $1,127,955 | ZRG1 |
| 2015 | Development of a DIVI platform for issue resolution in pre-clinical drug development.1R44GM113304-01A1 | WAMHOFF, BRIAN ROBERT | HEMOSHEAR THERAPEUTICS, LLC, VA | $1,126,395 | ZRG1 |
| 2015 | Development of Small Molecule Therapeutics Against Smallpox and Other Poxviruses1R44AI115759-01 | SCOTT, RICHARD W | FOX CHASE CHEMICAL DIVERSITY CENTER, INC, PA | $1,110,810 | ZRG1 |
| 2015 | A Phase IIa Study of rHuIL-12 as an Immunotherapy and Radiomitigator for CTCL Patients Receiving Radiotherapy1R44CA192576-01 | BASILE, LENA A. | NEUMEDICINES, INC., CA | $1,088,333 | ZRG1 |
| 2015 | Clinical Evaluation of a Novel Prostate Cancer PET Diagnostic1R44CA192451-01 | LANGTON-WEBSTER, BEATRICE | CANCER TARGETED TECHNOLOGY, LLC, WA | $1,076,087 | ZRG1 |
| 2015 | Oxygen Mapping System for Enhanced Colonoscopic Neoplasm Detection1R44CA192460-01 | ZAND, JASON MATTHEW | SURGISENSE CORPORATION, MD | $1,072,220 | ZRG1 |
Showing the 200 most recent of 248 awards.
Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-09-0.1.0. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.